生命科学仪器2026，Vol.24Issue(1)：25-27,3.DOI:10.11967/2026240209
SOX10、GATA3和P16联合检测在三阴性乳腺癌诊断中的价值分析
Value Analysis of Combined Detection of SOX10、GATA3 And P16 in The Diagnosis of Triple Negative Breast Cancer
童晶 1杨永国1
作者信息
- 1. 扬州市江都人民医院病理科,江苏 扬州 225200
- 折叠
摘要
Abstract
Objective:To explore and analyze the clinical value of combined detection of SOX10,GATA3 and P16 in the diagnosis of triple negative breast cancer.Methods:274 cases of breast cancer collected by the Pathology Depart-ment of Jiangdu People's Hospital in Yangzhou City from January 2020 to December 2024 were selected as the re-search objects,including 76 cases of triple-negative breast cancer and 198 cases of non-triple-negative breast cancer,which were respectively set as the research group and the control group.Immunohistochemical examination was used in both groups to compare the positive expression rates of SOX10、GATA3 and P16,and to analyze the re-lationship between GATA3、SOX10 and P16 and clinicopathological features and diagnostic efficiency.Results:The positive expression rate of P16 and SOX10 in the study group was significantly higher than that in the control group,and the positive expression rate of GATA3 was significantly lower than that in the control group(P<0.05).There were no significant differences in GATA3、SOX10 and P16 in age,tumor size and lymph node metas-tasis(P>0.05),but there were significant differences in histological grading(P<0.05).The diagnostic sensitivity and specificity of GATA3 for triple negative breast cancer were 41.50%and 92.00%.The diagnostic sensitivity and specificity of SOX10 were 75.50%and 94.00%.The diagnostic sensitivity and specificity of P16 were 41.50%and 96.00%,respectively.Conclusion:SOX10、GATA3 and P16 can improve the diagnostic efficiency of triple neg-ative breast cancer and provide scientific guidance for clinical treatment.关键词
三阴性乳腺癌/非三阴性乳腺癌/免疫组化检验/诊断效能Key words
Triple negative breast cancer/Non-triple negative breast cancer/Immunohistochemical test/Diagnostic efficiency分类
医药卫生引用本文复制引用
童晶,杨永国..SOX10、GATA3和P16联合检测在三阴性乳腺癌诊断中的价值分析[J].生命科学仪器,2026,24(1):25-27,3.
